以手機監測心臟健康 醫學院的兩項獲獎發明，結合人工智能（AI）與行動裝置 技術，讓人們僅需使用手機便能有效監測心臟健康與血 壓狀況。 無論是心臟監測儀 Vitogram®還是血壓監測儀 Sphygmio，均由生物醫學學院何永基教授帶領研發。 Vitogram®被譽為「口袋裡的AI醫生」，因其能收集並分析 心臟聲音――而多數數�健康裝置僅專注於脈搏與電生理 活動。此發明於2024年第49屆日內瓦國際發明展榮獲「評 判特別嘉許金獎」。 何教授指出：「分析心臟聲音至關重要，因為它能提供與 醫生使用聽診器所獲取的健康數據相當的信息。我們的系 統讓任何人都能使用普通智能手機，只需將裝置置於胸 前，即可便捷評估心臟健康狀況。」 若檢測到心音異常，使用者可及時就醫，使該發明成為早 期偵測瓣膜性心臟病、心律異常及實現個人化健康管理的 重要工具。醫學院臨床研究證實，這套基於手機的AI系統 能精準檢測因嚴重瓣膜性心臟病引發的異常心音，準確度 可媲美醫生使用聽診器評估的結果。 另一款血壓監測儀Sphygmio由何教授指導的博士生 郭子然研發，透過運用行動裝置內建感測器（如麥克風、 動作感應器與鏡頭）來測量血壓及其他生命徵象。此技術 可整合至遙距醫療系統，未來更有望應用於緊急救護，同 時能實現高擴展性的高血壓藥物劑量優化管理，並保障使 用者隱私。 Sphygmio於2025年第50屆日內瓦國際發明展榮獲「評判 特別嘉許金獎」。 郭子然表示：「血壓量測是評估中風風險、心血管健康與 長期身體狀況的關鍵生命徵象。傳統血壓監測方式多需使 用壓脈帶裝置，在緊急情況或遙距醫療情境中難以實行。 Sphygmio提供的創新方案正能解決這些問題。」 兩項裝置均以成果轉化與商業化為目標。Vitogram®的研 發靈感源自新冠疫情期間患者避免外出就診的醫療困境。 該裝置現已於美國食品及藥物管理局完成醫療器材註冊。 港大醫學院已成立衍生公司Vitome Limited，旨在將 Vitogram®與Sphygmio兩項技術推出市場。 這些計劃獲得中華人民共和國香港特別行政區政府創新 科技署「AIR@InnoHK」平台資助，該平台致力加速科研 成果轉化為臨床應用與商業產品。 Another blood pressure monitor, Sphygmio, was developed by Mr Nicholas Kwok Tse-yin, whose PhD supervisor is Professor Ho. It uses built-in sensors in mobile devices, such as microphones, motion sensors and cameras, to measure blood pressure and other vital signs. This capability can be integrated with telemedicine and may eventually be useful for emergency care. It could also enable scalable drug dosage optimisation for hypertension management, while protecting user privacy. Sphygmio won a Gold Medal with Congratulations of the Jury at the 50th IEIG this year. ‘Blood pressure measurement is a vital sign that is significant for assessing stroke risk, cardiovascular health and long-term wellness,’ said Mr Kwok. ‘Traditional blood pressure monitoring methods often involve cumbersome cuff-based devices, which can be impractical in emergencies or telemedicine situations. Sphygmio offers an innovative solution that can address these concerns.’ The devices are being developed with an eye to translation and commercialisation. Vitogram®, which was inspired by healthcare challenges during the COVID-19 pandemic, when patients often avoided going out and seeking medical care, has been registered with the US Food and Drug Administration as a medical device. A HKUMed spin-off company, Vitome Limited, has also been established to bring both Vitogram® and Sphygmio to market. The projects have received funding support from the AIR@InnoHK platform of the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China. The funding supports the rapid translation of scientific research into clinical applications and commercialisation. 11 HKUMed News Winter 2025
RkJQdWJsaXNoZXIy Mzg4NDg0